OS Therapies to Host Analyst Day at NYSE on April 7, 2025

Rhea-AI Summary

OS Therapies (NYSE-A: OSTX) has announced an upcoming Analyst Day event at the New York Stock Exchange on April 7, 2025 at 10am ET. The clinical-stage biopharmaceutical company will present key developments in their immunotherapy and Antibody Drug Conjugate programs.

The event will spotlight three main areas:

• The OST-HER2 program for human recurrent lung metastatic osteosarcoma, targeting Accelerated Approval in late 2025
• Canine osteosarcoma treatments seeking conditional approval in H2 2025
• OST-HER2 applications in breast cancer and other solid tumors

Additionally, the company will discuss their pipeline acquisitions from Ayala Pharmaceuticals and their tunable drug conjugates (tDC) & antibody drug conjugates (tADC) platform. The event will be held at 18 Broad St, New York, with attendees requested to arrive at 9:30am ET for security clearance.

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the Company will be hosting an Analyst Day at the New York Stock Exchange in Lower Manhattan that will start at 10am on Monday, April 7, 2025.

The Company intends to focus the Analyst Day discussion on:

• OST-HER2 program for human recurrent, fully resected lung metastatic osteosarcoma that is being positioned for Accelerated Approval in late 2025
• OST-HER2 program for canine osteosarcoma that is being positioned for conditional approval in the second half of 2025, and plans for full approval
• OST-HER2 data in breast cancer, and other human solid tumors to be pursued immediately after approval of OST-HER2 in osteosarcoma

Additionally, the Company will review the pipeline of assets being acquired from Ayala Pharmaceuticals, and potential of our tunable drug conjugates (tDC) & antibody drug conjugates (tADC) platform.

Event Information

Title:			OS Therapies NYSE Analyst Day
Location:			New York Stock Exchange, 18 Broad St, New York, NY 10005
Date:			April 7, 2025 @ 10am ET (arrive at 9:30am ET to allow security clearance)
Reservation:			https://www.moneyballnetworks.com/nyse-analyst-day-april7

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250402090200/en/

OS Therapies Contact Information:

Jack Doll

410.297.7793

Irpr@ostherapies.com



https://x.com/OSTherapies

https://www.instagram.com/ostherapies/

https://www.facebook.com/OSTherapies/

https://www.linkedin.com/company/os-therapies/

Source: OS Therapies

FAQ

When and where is OS Therapies (OSTX) hosting their Analyst Day in 2025?

OS Therapies is hosting their Analyst Day on April 7, 2025, at 10am ET at the New York Stock Exchange (18 Broad St, New York). Attendees should arrive at 9:30am for security clearance.

What are the key programs OSTX will discuss at their 2025 Analyst Day?

OSTX will discuss their OST-HER2 program for lung metastatic osteosarcoma, canine osteosarcoma treatments, breast cancer applications, and their tunable drug conjugates platform.

When does OSTX expect approval for their OST-HER2 osteosarcoma treatment?

OSTX is targeting Accelerated Approval for human osteosarcoma treatment in late 2025, with conditional approval for canine osteosarcoma in the second half of 2025.

What pipeline assets will OSTX present at the 2025 NYSE Analyst Day?

OSTX will present their acquired pipeline assets from Ayala Pharmaceuticals and discuss their tunable drug conjugates (tDC) & antibody drug conjugates (tADC) platform.

How can investors attend the OSTX Analyst Day at NYSE?

Investors can make reservations for the OSTX Analyst Day through the MoneyBall Networks website at moneyballnetworks.com/nyse-analyst-day-april7.